FGFR2 and breast cancer: Specifically, tumor-associated fibroblasts (TAFs), a type of stromal cell in the TME, have been implicated in promoting trastuzumab resistance via fibroblast growth factor receptor 2 (FGFR2) activation in HER2+ BC cells (Figure 2D).